Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board

MILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the addition of Johnny Bennett, Ph.D. to its Scientific Advisory Board. Dr. Bennett currently serves as Vice President, and Head of Discovery Chemistry at Merck Research Laboratories.

Eikon has a long-standing relationship with Merck (known as MSD outside of the US and Canada). Merck has provided their anti-PD-1 therapy, KEYTRUDA(®) (pembrolizumab), for registration-enabling trials involving EIK1001, Eikon’s systemically administered TLR7/8 dual agonist, and for initial combination studies with EIK1005, Eikon’s proprietary Werner helicase inhibitor. In addition, Merck participated in Eikon’s initial public offering. Eikon and Merck have now agreed to further this ongoing relationship by adding Dr. Bennett to Eikon’s most senior external scientific advisory group.